These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 348088)

  • 41. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).
    Breithaupt H; Pralle H; Eckhardt T; von Hattingberg M; Schick J; Löffler H
    Cancer; 1982 Oct; 50(7):1248-57. PubMed ID: 7104969
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Bhalla K; McCrady C
    Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine.
    Schwendener RA; Schott H
    Int J Cancer; 1992 May; 51(3):466-9. PubMed ID: 1592536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I study of 5-fluorodeoxyuridine plus cytosine arabinoside infusions in patients with solid tumors.
    Cummings FJ; Hoovis ML; Calabresi P
    Cancer Treat Rep; 1979 Aug; 63(8):1371-4. PubMed ID: 157808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
    Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A preclinical evaluation of cytarabine prodrug nanofibers assembled from cytarabine-lauric acid conjugate toward solid tumors.
    Liu R; Jiang Y; Hu X; Wu J; Jiang W; Jin G; Luan Y
    Int J Pharm; 2018 Dec; 552(1-2):111-118. PubMed ID: 30268848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of tetrahydrouridine on metabolism and transport of 1-beta-D-arabinofuranosylcytosine in human cells.
    Riva C; Barra Y; Carcassonne Y; Cano JP; Rustum Y
    Chemotherapy; 1992; 38(5):358-66. PubMed ID: 1286578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer.
    Schilsky RL; Muscato JJ; Muscato MS; Perry MC
    Cancer Treat Rep; 1984 Sep; 68(9):1097-102. PubMed ID: 6541094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
    Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
    Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor characteristics of the conjugate of N4-(4-carboxybutyryl)-ara-C with ethylenediamine-introduced dextran and its resistance to cytidine deaminase.
    Onishi H; Pithayanukul P; Nagai T
    Drug Des Deliv; 1990 Oct; 6(4):273-80. PubMed ID: 1707277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The disposition of cytosine arabinoside and its metabolite after single doses to rabbits.
    Zimmerman CL
    Biopharm Drug Dispos; 1990 Mar; 11(2):121-9. PubMed ID: 2328297
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
    Laliberté J; Marquez VE; Momparler RL
    Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine.
    Capizzi RL; White JC; Powell BL; Perrino F
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):54-69. PubMed ID: 1780754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical use of intermediate to high dose of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in children with acute leukemia.
    Takashima Y
    J Clin Pharmacol; 1988 Apr; 28(4):356-62. PubMed ID: 3164731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
    Ohno R; Kimura K
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1205-8. PubMed ID: 3382195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro sensitivity of various human tumors to 1-beta-D-arabinofuranosylcytosine and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Maehara Y; Kusumoto T; Kusumoto H; Anai H; Sugimachi K
    Chemotherapy; 1989; 35(3):181-6. PubMed ID: 2766858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
    Heinemann V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1989 May; 7(5):622-8. PubMed ID: 2709090
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
    Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.
    Momparler RL; Eliopoulos N; Bovenzi V; Létourneau S; Greenbaum M; Cournoyer D
    Cancer Gene Ther; 1996; 3(5):331-8. PubMed ID: 8894252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.